16 July 2025

Physiomics plc
("Physiomics" or the "Company")

Physiomics Awarded New Contract by Numab Therapeutics

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract with its valued and long-standing client, Numab Therapeutics AG.

This project will use PK/PD modelling and simulation approaches to inform understanding and selection of appropriate clinical dosing for a First In Human ("FiH") study for an antibody in Numab Therapeutics' Inflammation pipeline. The work for this project is expected to begin imminently and is expected to complete within the next six months.

This project represents another important step in our ongoing collaboration applying Model Informed Drug Development ("MIDD") to support a data-driven approach to drug development and in this case FiH dose selection.

Dr Peter Sargent, CEO of Physiomics, commented:

"We're delighted to be deepening our existing relationship with Numab Therapeutics through this new project. Applying our MIDD expertise to support early clinical development aligns perfectly with our mission to help clients make smarter, faster decisions that can help de-risk development and improve outcomes. We are also pleased to be supporting the development of a therapy targeting inflammation, demonstrating our service expansion beyond oncology."

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

Physiomics plc
Dr Peter Sargent, CEO
+44 (0)1235 841575

Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics

team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

END

CNTGPUBPMUPAGCA